Commentary
“Financial discipline has been one of the hallmarks of the Company, and for the last 19 years
Darren has provided stability, and strong leadership,” CLINUVEL’s CEO, Dr Philippe Wolgen said.
“He has been with CLINUVEL from its turnaround in 2005 to help it become one of the few
profitable pharmaceuticals launching new molecular entities in the Southern hemisphere.
“Darren leaves the Company in a superior financial position. On behalf of the Board and staff, I
wish him well in his future endeavours as he hands over to Peter.
https://www.clinuvel.com/wp-content/uploads/2024/04/20240415-change-to-executive-management.pdf
Commentary“Financial discipline has been one of the hallmarks of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.015(5.36%) |
Mkt cap ! $77.89M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.5¢ | $383.3K | 1.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 661904 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 95042 | 12 |
View Market Depth
| Last trade - 14.48pm 31/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |